Effectiveness of maintenance treatments for nonsmall cell lung cancer

Matthew J Eadens, Steven I Robinson, Katharine AR PriceDivision of Medical Oncology, Mayo Clinic, Rochester, MN, USAAbstract: Maintenance therapy for advanced nonsmall cell lung cancer has shown some clinical benefit for patients by improving progression-free survival and, to a lesser extent, overal...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Eadens MJ, Robinson SI, Price KA
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2011
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/90c5a1acfc5a43d99148aab98eb8272c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:90c5a1acfc5a43d99148aab98eb8272c
record_format	dspace
spelling	oai:doaj.org-article:90c5a1acfc5a43d99148aab98eb8272c2021-12-02T06:33:44ZEffectiveness of maintenance treatments for nonsmall cell lung cancer1179-2728https://doaj.org/article/90c5a1acfc5a43d99148aab98eb8272c2011-07-01T00:00:00Zhttp://www.dovepress.com/effectiveness-of-maintenance-treatments-for-nonsmall-cell-lung-cancer-a7929https://doaj.org/toc/1179-2728Matthew J Eadens, Steven I Robinson, Katharine AR PriceDivision of Medical Oncology, Mayo Clinic, Rochester, MN, USAAbstract: Maintenance therapy for advanced nonsmall cell lung cancer has shown some clinical benefit for patients by improving progression-free survival and, to a lesser extent, overall survival. Two main strategies exist for maintenance therapy, ie, continuation and switch maintenance. Continuation maintenance involves the continued use of one of the induction drugs beyond 4&ndash;6 cycles of initial treatment. Switch maintenance utilizes a third agent initiated after first-line chemotherapy. Both cytotoxic agents and targeted agents have been studied. Switch maintenance therapy with pemetrexed in nonsquamous tumors and erlotinib appear to show the most clear clinical benefit. Continuation maintenance with bevacizumab has shown improvement in progression-free survival. Data concerning the role of cetuximab for maintenance is conflicting. Toxicity, quality of life, and cost are important confounding issues that need to be considered. Several ongoing Phase III trials are investigating strategies to improve on the current agents as well as testing promising new therapies.Keywords: lung cancer, chemotherapy, maintenance therapy, targeted therapyEadens MJRobinson SIPrice KADove Medical PressarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENLung Cancer: Targets and Therapy, Vol 2011, Iss default, Pp 29-39 (2011)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Eadens MJ Robinson SI Price KA Effectiveness of maintenance treatments for nonsmall cell lung cancer
description	Matthew J Eadens, Steven I Robinson, Katharine AR PriceDivision of Medical Oncology, Mayo Clinic, Rochester, MN, USAAbstract: Maintenance therapy for advanced nonsmall cell lung cancer has shown some clinical benefit for patients by improving progression-free survival and, to a lesser extent, overall survival. Two main strategies exist for maintenance therapy, ie, continuation and switch maintenance. Continuation maintenance involves the continued use of one of the induction drugs beyond 4&ndash;6 cycles of initial treatment. Switch maintenance utilizes a third agent initiated after first-line chemotherapy. Both cytotoxic agents and targeted agents have been studied. Switch maintenance therapy with pemetrexed in nonsquamous tumors and erlotinib appear to show the most clear clinical benefit. Continuation maintenance with bevacizumab has shown improvement in progression-free survival. Data concerning the role of cetuximab for maintenance is conflicting. Toxicity, quality of life, and cost are important confounding issues that need to be considered. Several ongoing Phase III trials are investigating strategies to improve on the current agents as well as testing promising new therapies.Keywords: lung cancer, chemotherapy, maintenance therapy, targeted therapy
format	article
author	Eadens MJ Robinson SI Price KA
author_facet	Eadens MJ Robinson SI Price KA
author_sort	Eadens MJ
title	Effectiveness of maintenance treatments for nonsmall cell lung cancer
title_short	Effectiveness of maintenance treatments for nonsmall cell lung cancer
title_full	Effectiveness of maintenance treatments for nonsmall cell lung cancer
title_fullStr	Effectiveness of maintenance treatments for nonsmall cell lung cancer
title_full_unstemmed	Effectiveness of maintenance treatments for nonsmall cell lung cancer
title_sort	effectiveness of maintenance treatments for nonsmall cell lung cancer
publisher	Dove Medical Press
publishDate	2011
url	https://doaj.org/article/90c5a1acfc5a43d99148aab98eb8272c
work_keys_str_mv	AT eadensmj effectivenessofmaintenancetreatmentsfornonsmallcelllungcancer AT robinsonsi effectivenessofmaintenancetreatmentsfornonsmallcelllungcancer AT priceka effectivenessofmaintenancetreatmentsfornonsmallcelllungcancer
_version_	1718399886997585920

Effectiveness of maintenance treatments for nonsmall cell lung cancer

Ejemplares similares